Effects of low doses of aerosolized iloprost combined with tadalafil in treatment of adult congenital heart disease with severe pulmonary arterial hypertension.
Caojin Zhang,Yigao Huang,Tao Huang,Chunli Xia,Xinsheng Huang,Guolin Zhang,Jimei Chen,Jiyan Chen,Jian Zhuang
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132440
IF: 6.133
2014-01-01
Chinese Medical Journal
Abstract:Pulmonary arterial hypertension (PAH) is a common and serious complication of congenital heart disease (CHD). Many studies have confirmed that the prostacyclin analogues, 5-phosphodiesterase (PDE-5) inhibitors, and endothelin receptor antagonists, were safe and effective in the treatment for PAH due to CHD.1,2 But whether the combination of targeted PAH therapy drugs provides similar synergistic effects is still controversial.1,2 Therefore, we investigated whether adult patients with severe PAH secondary to CHD would benefit from iloprost combined with low-dose tadalafil. METHODS Adult (age >18 years) patients in Guangdong General Hospital with severe PAH secondary to CHD were enrolled in this study. Severe PAH is defined as pulmonary vascular resistance (PVR) ≥10 Wood units, the pulmonary vascular resistance vs. systemic vascular resistance (Rp/Rs) ratio ≥2/3, Qp/Qs <1.5, and pulmonary capillary wedge pressure (PCWP) less than 15 mmHg. Exclusion criteria were as following: (1) combined with severe obstructive lung disease, forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) <0.5; (2) total lung capacity less than 60% of the predicted normal value; (3) mental illness, history of drug addiction or other conditions which make the patient unable to sign informed consent or cooperate in the clinical study; (4) patients who are receiving treatment with prostacyclin or its analogues, endothelin receptor antagonist, L-arginine, and PDE-5 inhibitors, or patients who concluded treatment <3 months previous; (5) lower limb conditions that affect the 6-minute walking test (6MWT); (6) increased risk of bleeding disorders (e.g., active peptic ulcer disease, trauma, intracranial bleeding or other bleeding); (7) patients suffering from other serious heart diseases, such as serious arrhythmias, severe coronary heart disease, unstable angina, incidence of myocardial infarction within the past six months; (8) low circulation pressure patients (systolic blood pressure less than 85 mmHg); (9) cerebrovascular events occurred nearly three months (such as transient ischemic attack, stroke) or other cerebral circulation disorders; (10) pregnancy, breast-feeding; (11) PH due to left-heart disease, lung disease/hypoxia, or miscellaneous disease. Patients who meet the inclusion criteria were enrolled in this study. All patients received iloprost (Ventavis, Bayer Schering Pharmaceutical Co., Ltd.) 2.5 μg per inhalation and six times per day. After six months, tadalafil was added using a low dose (5 mg once daily). At baseline and at 6 and 12 months, all patients underwent a 6MWT, Borg dyspnea score, oxygen saturation measurement, WHO functional classification, and cardiac catheterization. All patients had adverse events carefully recorded by researchers during the whole study. The study was approved by the Institutional Ethics Committee at Guangdong General Hospital. Written informed consent was obtained from all patients prior to enrollment. Data are expressed as mean±standard deviation (SD). The parameters within groups before and after treatment were compared using a paired t-test. A level of significance of 5% was chosen and all tests were two-sided. Statistical calculations were performed using SAS software version 8.1. RESULTS From January 2007 to December 2010, 63 patients with severe PAH secondary to CHD were enrolled in this study. Forty-seven of them (29 women and 18 men with a mean age of (30.9±8.6) years) completed the entire 12-month study period. Patient diagnosis included 24 atrial septal defect (ASD) cases, 15 ventricular septal defect (VSD) cases, five patent ductus arteriosus (PDA) cases, and three with Atrioventricular septal defect. Compared with baseline data (Table 1), after inhaled iloprost, there was a significant decrease in PVR and in the Rp/Rs ratio, and a significant increase in the estimated left-to-right shunt. This resulted in an improvement in the Qp/Qs ratio and significant improvement in systemic oxygen saturation (SaO2), pulmonary oxygen saturation (PaO2) and mixed venous oxygen saturation (SvO2). At the end of 12 months, there was a further significant reduction in PVR compared with that obtained at six months, along with a significant improvement in SaO2 and SvO2, and especially in PaO2. Iloprost combined with tadalafil mediated significant decreases in pulmonary artery pressure, while no significant decrease was noted in aortic pressure.Table 1: Comparison of hemodynamic data before and after treatment in 47 patientsAt the end of six months, all patients showed an improvement in the WHO functional class by at least one grade (Figure 1). Similarly, all patients showed improvement in the 6MWD from (421.41±68.81) m to (457.22±59.75) m (P <0.05). Meanwhile, the Borg Dyspnea score decreased from 2.5±0.88 to 2.06±0.86 (P <0.05). Compared with values obtained at six months (Figure 1), when adding tadalafil to iloprost for six months, there was a further significant improvement in WHO functional class from 2.04±0.59 to 1.85±0.55 (P=0.002). The 6MWD also increased from (457.22±59.75) m to (490.09±50.29) m (P <0.05). Borg dyspnea score continued to decrease from 2.06±0.86 to 1.67±0.76 (P< 0.05). The systemic oxygen saturation during exercise also increased significantly from (82.1±9.4)% to (85.4±12.1)% (P< 0.05).Figure 1.: Changes of WHO functional class in 47 patients before and after treatment.Seven patients reported 12 adverse effects during the 12-month study period. Five patients experienced one or more adverse effects. The adverse effects included flushing (n=3), headache (n=3), nasal tampon (n=1), and lip rash (n=1). Most adverse effects were mild to moderate in intensity and generally subsided within several days of the initiation of inhalation. Abnormal short menstrual cycle and hypervolemia in two female patients was reported after tadalafil administration. Other adverse events, such as muscle pain, nasal congestion, indigestion, and diarrhea have been reported by other researchers, but were not found during the study. DISCUSSION Some clinical trials have shown that iloprost reduced PVR.1-4 Interestingly, a study using low-dose iloprost (0.5 ng·kg−1·min−1) intravenously demonstrated equal effectiveness as the high dose (2 ng·kg−1·min−1) in the long-term treatment of systemic sclerosis.5 Sun et al4 reported that the low-dose iloprost inhalation significantly improved exercise capacity and functional status in patients with PAH. Our study showed that low-dose iloprost inhalation for six months could markedly decrease PVR and the Rp/Rs ratio, and significantly improve SaO2 and pulmonary blood flow. Therefore, we concluded that adult patients with PAH secondary to CHD would also benefit from inhaled low-dose iloprost. Sun et al4 found that the improvement of hemodynamics was seen in patients with WHO functional class I-II but not in patients with WHO functional class III-IV. Somewhat differently, all patients showed an improvement in WHO functional class by at least one grade in the present study. We hypothesize that the reaction to iloprost in patients with PAH due to CHD is relatively sensitive compared to other causes. Moreover, the varying condition of patients selected into the study may influence the outcome. In this study, iloprost combined with low-dose tadalafil markedly improved the patients' cardiac hemodynamic parameters, especially improving SaO2 after exercise. Therefore, we thought that in the patients who were response to iloprost monotherapy, iloprost combined with low-dose tadalafil could further reduce PVR and increase cardiac output, and not affect their systemic blood pressure and heart rate. When combing these two drugs, tadalafil can make up the disadvantage of the short half-life of iloprost, and make it more effective and stable for improving the patient's hemodynamic status. This is also the reason that the efficiency of iloprost combined with a low dose of tadalafil is better than the iloprost monotherapy in the present study. In conclusion, the inhalation of low-dose iloprost can reduce the PVR, increase pulmonary blood flow in CHD patients with PAH, and the addition of low-dose tadalafil can further reduce the patient's pulmonary arterial pressure and PVR. The results suggest that low-dose tadalafil may effectively increase the efficacy of inhaled iloprost in treatment of PAH. However, there are also some limitations, such as the small sample size and short observation time. Therefore, more solid evidence is necessary in confirming the combination therapy as an effective treatment strategy for severe PAH.